LETTER TO THE EDITORS

Reply to Rodriguez-Peralvarez et al

Wojciech G. Polak1, Constantino Fondevila2, Vincent Karam3, Rene Adam4, Luca S. Belli5, Christophe Duvoux6 & for European Liver, Intestine Transplant Association (ELITA), the COVID-19 ELITA Study Group

1 Department of Surgery, Division of HPB and Transplant Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
2 Department of General and Digestive Surgery, Liver Transplant Unit, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain
3 European Liver Transplant Registry, Centre Hépatobiliaire, Hôpital Universitaire, Paul Brousse, Villejuif, France
4 Department of Hepatobiliary Surgery, Cancer and Transplantation, AP-HP Hôpital Universitaire Paul Brousse, Villejuif, France
5 Division of Hepatology and Gastroenterology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
6 Medical Liver Transplant Unit and Liver Department, Henri Mondor Hospital AP-HP, Paris Est University, Champs-sur-Marne, France
E-mail: w.polak@erasmusmc.nl

To the Editors:

We read with great interest the letter by Rodriguez-Peralvarez et al. where the authors discuss the incidence of COVID-19 in liver transplant (LT) recipients in Europe and comment on the results of the recently published early survey of European Liver and Intestine Transplantation Association (ELITA) and European Liver Transplant Registry (ELTR) [1,2].

In their letter, Rodriguez-Peralvarez et al. highlight that the cumulative incidence of COVID-19 in LT recipients was highly variable in different European countries at the time of our survey. This was clearly shown in our study (Fig. 1) where the heterogeneity of COVID-19 prevalence across Europe was presented. In the same figure, we showed that the cumulative incidence of COVID-19 in Spain was 0.79%, which corresponds to that reported by the authors in their excellent nationwide study (0.84%) [3]. However, in contrast to the national studies, the strength of our ELITA-ELTR study is a better description of the incidence of COVID-19 in LT recipients at the European level at the beginning of the pandemic. Another important finding of our study was that a higher incidence of COVID-19 in LT recipients compared to general population was not observed in all countries, in contrast to the incidence of COVID-19 in LT candidates. However, we took care to mention in our paper that the crude incidence proportions were an estimate obtained in difficult conditions in the middle of the epidemic and without any adjustment for gender and age.

We recognize that the definition of symptomatic COVID-19 in LT candidates/recipients used in our study was broad (relevant clinical symptoms and positive swab PCR and/or highly suggestive lung injury on thoracic CT scan), and as mentioned by the authors, this could be the reason for overestimation of the incidence of COVID-19 in some centres compared to the authors’ study [1]. However, in our opinion, the broader definition was more appropriate for a preliminary study attempting to estimate the frequency COVID-19 in LT candidates and recipients across Europe, knowing that the sensitivity of the nasopharyngeal swap PCR is 70–80% [4]. At the same time, studies conducted in centres with a high incidence of COVID-19 have reported that negative RT-PCR test, but with positive CT features, should be highly suggestive for COVID-19 [4–6].

In summary, the ELITA-ELTR snapshot survey on COVID-19 in LT recipients and candidates, despite some limitations, provided the first reliable information on the incidence of COVID-19 in this population across Europe, taking actually into account national variations and reflecting at best in our opinion the reality of the landscape. The consistency between rates of COVID-19 in Spain as reported in our study, and in the Spanish one, strongly support this assumption. National scale projects such as the Spanish study in LT recipients will complement this information to provide detailed information on the epidemiological situation of COVID-19.
in different European countries. Combining data from all European countries in one platform/study would provide a unique opportunity to monitor the incidence of COVID-19 in liver transplantation setting, adding a dynamic dimension to our first report, and most importantly to collect additional information on treatment strategies to optimize the management of COVID-19 in the very special population of LT recipients.

**Funding**
The authors have no funding.

**Conflict of interest**
The authors have declared no conflict of interest.

**REFERENCES**

1. Rodríguez-Perálvarez M, Salcedo M, Colmenero J, Pons JA, Spanish Society of Liver Transplantation (SETH). Increased incidence of Covid-19 among liver transplant patients in Europe. *Transpl Int* 2020; https://doi.org/10.1111/tri.13729

2. Polak WG, Fondevila C, Karam V, *et al.* Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry. *Transpl Int* 2020; 33: 1244.

3. Colmenero J, Rodríguez-Perálvarez M, Salcedo M, *et al.* Epidemiological pattern, incidence and outcomes of COVID-19 in liver transplant patients. *J Hepatol* 2020; S0168–8278(20)30521–3. https://doi.org/10.1016/j.jhep.2020.07.040

4. Long C, Xu H, Shen Q, *et al.* Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? *Eur J Radiol* 2020; 126: 108961.

5. Giannitto C, Sposta FM, Repici A, *et al.* Chest CT in patients with a moderate or high pretest probability of COVID-19 and negative swab. *Radiol Med* 2020; 1–11. https://doi.org/10.1007/s11547-020-01269-w

6. Falaschi Z, Danna PSC, Arioli R, *et al.* Chest CT accuracy in diagnosing COVID-19 during the peak of the Italian epidemic: a retrospective correlation with RT-PCR testing and analysis of discordant cases. *Eur J Radiol* 2020; 130: 109192.